Coeliac disease (CD) is an inherited autoimmune condition triggered in genetically susceptible individuals by amino acid sequences within the prolamin fractions of ingested wheat (gliadins), barley (hordeins) and rye (secalins). Traditionally, treatment with a gluten-free (GF) diet has excluded these and also oats. Increasing evidence, however, suggests that oats can safely be included as part of the GF diet. Compared with wheat, barley and rye gluten, oat prolamin (avenin) constitutes a smaller proportion of the total seed protein, and contains fewer potentially toxic proline residues. Recent randomized controlled trials from Scandinavia suggest that oats have no impact on the duodenal histology or serum antibody levels of patients with CD. Janatuinen et al. [1] demonstrated that the addition of oats (mean daily intake of 50 g daily) to a GF diet allowed symptomatic and histological remission in newly diagnosed adults with CD after 12 months and the maintenance of remission in treated patients over 6 months. Subsequently, patients who continued to take oats with no evidence of histological or serological deterioration after 5 years were reviewed [2] . Similarly, Hogberg et al. [3] randomized newly diagnosed children with CD to GF diets with and without oats and reported no difference in histology between the two groups after 12 months. Holm et al. [4] randomized children in remission to oats or gluten challenge with maintenance of remission in the first group up to 2 years. Other uncontrolled, observational studies showing oats safety have been summarized by Garsed and Scott [5] . The safety or otherwise of oats, however, becomes academic if patients with CD are consuming oat products which have been significantly contaminated with more toxic cereals.
In a study published in this issue, Hernando et al. [6] assessed commercially available oat products for contamination by wheat, barley and rye. Barley contamination is a particular issue: not only is barley often rotated with, and processed alongside, oats, but the gliadin antibody ELISA assay used in a number of commercial kits to assess gluten contamination [7] does not recognize hordeins. The authors used an ELISA based on the monoclonal antibody R5, which recognizes the potentially toxic QQPFP pentapeptide found in gliadins, hordeins and secalins but not in avenins. This technique has already been validated by the Working Group on Prolamin Analysis and Toxicity [8] . Use of a hordein as well as a gliadin standard avoided the tendency of this assay to overestimate hordein levels, and quantitative polymerase chain reaction and western blot techniques were used to identify the contaminant cereals and exclude the possibility of R5 cross-reactivity with avenins.
Complete gluten exclusion is difficult, and many coeliac patients can tolerate small amounts of gluten. The current Codex Alimentarius standard accepts a gluten content of 20 ppm in naturally GF food and 200 ppm in products 'rendered GF'. Although pure oats were confirmed as having undetectable levels of wheat, barley and rye prolamins, many commercial oat products had unacceptable levels of barley/wheat/rye contamination, with 41% (hordein standard)/59% (gliadin standard) of oat foods exceeding the 200 ppm limit and a further 26%/12% in the 20-200 ppm range. Barley was the predominant contaminant, with wheat and rye in addition in some products. In many cases, contaminants existed as a powder on the oat grain surface and could be removed effectively with aqueous ethanol, suggesting that straightforward decontamination of oats may be possible.
Why do we need to consider oats as part of a GF diet? Grain foods in the normal diet contribute a large proportion of the adult daily intake of B vitamins, minerals and fibre. A high proportion of CD patients, particularly women, taking a conventional GF diet failed to consume recommended daily amounts of fibre, iron and calcium [9] . Hallert et al. [10] reported impaired B vitamin status in patients on long-term gluten exclusion. Unlike many gluten-containing products, GF foods tend not to be enriched with vitamins and minerals [11, 12] . A median daily consumption of 93 g oats significantly improved intakes of iron, thiamine, zinc and fibre [13] . Oats are well recognized for their favourable glycaemic index [14] .
Further, particularly in countries where GF foods are not subsidized by national healthcare systems, specific GF products are substantially more expensive and less widely available than their gluten-containing equivalents [15] . Oat products may make the GF diet more palatable at lower cost. A median consumption of 93 g/day provided welcome variety, taste and satiety, with improved bowel action [13] . In 1997 the Finnish Coeliac Disease Society approved oat-containing GF products for adults with CD, extending to dermatitis herpetiformis patients in 1998 and children in 2000. A subsequent survey [16] showed that 70% of Finnish patients were consuming oats. The majority of consumers cited diversification of the diet, taste, availability/ease of use and low cost. Most children taking oats prefer to continue [4] . If oats make the GF diet generally more convenient and palatable, their consumption may have a positive impact on compliance, which is often suboptimal.
Not every coeliac patient can tolerate even pure oats. An appreciable dropout rate in many of the oat challenge studies owing to gut symptoms is observed, although these are often temporary, in most cases not associated with histological relapse, and are not significantly more common than in oat-free GF groups. Lundin et al. [17] , however, reported that one of 19 patients in remission developed villous atrophy and dermatitis herpetiformis after consuming 50 g oats per day. This case, and another two patients who developed villous atrophy with oats challenge, were shown to have oats avenin specific and reactive intestinal T cells [18] . Clearly, if oats are to be introduced into a GF diet, careful follow-up is needed to identify early any clinical deterioration. Although there are no clear guidelines to date, it would seem prudent to monitor patients commencing oats by clinical assessment, serology and possibly follow-up duodenal biopsy.
In the first instance, however, it is crucial to ensure that the patient with CD embarking on a GF diet with oats is using products that lack significant wheat, barley and rye content. The R5 ELISA assay shows that contamination is a significant problem, but should allow the reliable identification of oat products, meeting current and any future Codex guidelines, which patients with CD can consume with confidence. With CD affecting 0.5-1% of populations with European ancestry, there is a significant potential market for manufacturers who can supply uncontaminated oat products.
